Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.210
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.200
-0.010 (-0.83%)
After-hours: Apr 28, 2026, 4:09 PM EDT
Pliant Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
49
Market Cap
74.92M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 63.26M |
| ImmuCell | 27.64M |
| TScan Therapeutics | 10.33M |
| Immutep | 5.28M |
| aTyr Pharma | 190.00K |
PLRX News
- 10 days ago - Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting - GlobeNewsWire
- 5 weeks ago - Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Pliant Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - GlobeNewsWire
- 5 months ago - Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors - Benzinga
- 5 months ago - Pliant Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference - Transcripts
- 5 months ago - Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - GlobeNewsWire